Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
NpOF3 and NpOF4 can be produced by reacting neptunium oxides with anhydrous hydrogen fluoride at various temperatures. Neptunium also forms a wide variety of fluoride compounds with various elements. Some of these that have been characterized include CsNpF6, Rb2NpF7, Na3NpF8, and K3NpO2F5. Two neptunium chlorides, NpCl3 and NpCl4, have been characterized. Although several attempts to obtain NpCl5 have been made, they have not been successful. NpCl3 is produced by reducing neptunium dioxide with hydrogen and carbon tetrachloride (CCl4) and NpCl4 by reacting a neptunium oxide with CCl4 at around 500 °C. Other neptunium chloride compounds have also been reported, including NpOCl2, Cs2NpCl6, Cs3NpO2Cl4, and Cs2NaNpCl6. Neptunium bromides NpBr3 and NpBr4 have also been produced; the latter by reacting aluminium bromide with NpO2 at 350 °C and the former in an almost identical procedure but with zinc present. The neptunium iodide NpI3 has also been prepared by the same method as NpBr3.
==== NATO enlargement ==== Following the 2022 Russian invasion of Ukraine, Biden expressed support for expanding NATO to cover Sweden and Finland. On August 9, 2022, he signed the instruments of ratification stipulating U.S. support for the two countries' entry into NATO. Finnish ascension occurred on April 4, 2023, but opposition by Turkey and Hungary to Swedish entry led to a stalemate. Biden led diplomatic talks resulting in formal Swedish ascension into NATO on March 7, 2024. He has also expressed openness to Ukrainian entry into NATO following the end of the conflict, supporting an expedited timetable in its ascension and the removal of steps such as the Membership Action Plan typically required for NATO entry.
Applications of antipsychotic drugs in the treatment of schizophrenia include prophylaxis for those showing symptoms that suggest that they are at high risk of developing psychosis; treatment of first-episode psychosis; maintenance therapy (a form of prophylaxis, maintenance therapy aims to maintain therapeutic benefit and prevent symptom relapse); and treatment of recurrent episodes of acute psychosis. A recent 2024 study found that using high doses of antipsychotics for schizophrenia was linked to a higher risk of mortality. Researchers analyzed data from 32,240 individuals aged 17 to 64 diagnosed with schizophrenia between 2002 and 2012 to arrive at this conclusion.
=== Syngene International Ltd === Established in 1993, Syngene International Limited is a contract research and development organization (CDMO). In the CDMO space, Syngene primarily focuses on research innovation and manufacturing services for their clients. The company has four divisions: drug discovery services, dedicated research centres, development devices and manufacturing. Syngene works with eight of the top 10 global pharma companies and, Syngene's clients include Amgen, Zoetis, GlaxoSmithKline and Bristol Myers Squibb. Syngene has been expanding its operations. Since 2020, the company has opened an R&D centre in Hyderabad, is building an API manufacturing facility in Mangalore, which was scheduled to be commissioned in 2022, and has expanded their R&D facility in Bangalore. Syngene also provides biologics CDMO services. In July 2022, Syngene signed a 10-year agreement with Zoetis to manufacture the drug substance for Librela (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs. SynVent is Syngene's drug discovery and development platform for both small and large molecules. In September 2022, Biocon divested 5.4% of its shares in Syngene International. Clinigene International Limited is a subsidiary of Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.
Sources: en.wikipedia.org
Due to the glans' high sensitivity, direct stimulation to it is not always pleasurable; instead, direct stimulation to the hood or near the glans is often more pleasurable, with the majority of women preferring to use the hood to stimulate the glans, or to have the glans rolled between the labia, for indirect touch. It is also common for women to enjoy the shaft being softly caressed in concert with the occasional circling of the glans. This might be with or without digital penetration of the vagina, while other women enjoy having the entire vulva caressed. As opposed to the use of dry fingers, stimulation from well-lubricated fingers, either by vaginal lubrication or a personal lubricant, is usually more pleasurable for the external clitoris. As the clitoris' external location does not allow for direct stimulation by penetration, any external clitoral stimulation while in the missionary position usually results from the pubic bone area. As such, some couples may engage in the woman-on-top position or the coital alignment technique, a sex position combining the "riding high" variation of the missionary position with pressure-counterpressure movements performed by each partner in rhythm with sexual penetration, to maximize clitoral stimulation. Same-sex female couples may engage in tribadism (vulva-to-vulva or vulva-to-body rubbing) for ample or mutual clitoral stimulation during whole-body contact. Pressing the penis in a gliding or circular motion against the clitoris or stimulating it by the movement against another body part may also be practiced.
=== Multiplexed DIA (plexDIA) === The progress in data independent acquisition (DIA) enabled multiplexed quantitative proteomics with non-isobaric mass tags and a new method called plexDIA introduced in 2021. This new approach increases the number of data points by parallelizing both samples and peptides, thus achieving multiplicative gains. It has the potential to continue scaling proteomic throughput with new mass tags and algorithms. plexDIA is applicable to both bulk and single-cell samples and is particularly powerful for single-cell proteomics.
== Background == In the process of evolution, from one generation to the next the amino acid sequences of an organism's proteins are gradually altered through the action of DNA mutations. For example, the sequence
Erythritol (, US: ) is an organic compound, the naturally occurring achiral meso four-carbon sugar alcohol (or polyol). It is the reduced form of either D- or L-erythrose and one of the two reduced forms of erythrulose. It is used as a food additive and sugar substitute. It is synthesized from corn using enzymes and fermentation. Its formula is C4H10O4, or HO(CH2)(CHOH)2(CH2)OH. Erythritol is 60–70% as sweet as table sugar. However, erythritol is almost completely noncaloric and does not affect blood sugar or cause tooth decay. Japanese companies pioneered the commercial development of erythritol as a sweetener in the 1990s.
Vitamin D is a group of structurally related, fat-soluble compounds responsible for increasing intestinal absorption of calcium, along with numerous other biological functions. In humans, the most important compounds within this group are vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). Unlike the other twelve vitamins, vitamin D is only conditionally essential in the diet, as with adequate skin exposure to the ultraviolet B (UVB) radiation component of sunlight there is synthesis of cholecalciferol in the deeper layers of the skin's epidermis. Vitamin D can also be obtained through diet, food fortification and dietary supplements. For most people, skin synthesis contributes more than dietary sources. Accordingly, the name "vitamin D" is arguably a misnomer, as rather than being an essential part of the diet, it acts more like a fat-soluble secosteroid hormone precursor. Nevertheless, US and other dietary guidelines generally assume that all of a person's vitamin D is taken orally, given the potential for insufficient sunlight exposure due to urban living, cultural choices for the amount of clothing worn when outdoors, and use of sunscreen because of concerns about safe sunlight exposure. In many countries, milk and plant-based milk substitutes are fortified with vitamin D3, as are breakfast cereals. Cholecalciferol is converted in the liver to calcifediol (also known as calcidiol or 25-hydroxycholecalciferol), while ergocalciferol is converted to ercalcidiol (25-hydroxyergocalciferol).
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.